Halozyme Therapeutics Inc. (HALO) announced Wednesday morning that it has entered into a global collaboration and license agreement with AbbVie (ABBV) to develop and commercialize products combining proprietary AbbVie compounds with Halozyme's ENHANZE platform.
Halozyme Therapeutics gapped up Wednesday and climbed until mid-morning. The stock took out the session highs around mid-afternoon and closed up by 1.58 at $19.57 on above average volume. Halozyme has been rising for the past 3 weeks and set a new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News